HK Stock MarketDetailed Quotes

04332 Amgen Inc.

Watchlist
  • 0.000
  • 0.0000.00%
Trading Mar 19 09:30 CST
0Market Cap0.00P/E (TTM)

About Amgen Inc. Company

Amgen is committed to unlocking the biological potential of patients with serious diseases by discovering, developing, manufacturing and providing innovative human therapies. This method first uses advanced tools such as human genetics to reveal the complexity of diseases and understand the basics of human biology.

Company Profile

Listing Date06/01/1983
ChairmanGordon M Binder
Registered Office1840 Dehavilland Drive Thousand Oaks CA 91320-1789
Employees25200
Phone18054471060
Emailinvestor.relations@amgen.com
BusinessAmgen is a biotechnology company. The company explores, develops, manufactures and markets human therapeutic drugs. The company operates through the human therapeutic drug business. The drugs sold by the company include erythropoietin such as Neulasta (pegfilgrastim), Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa), Sensipar/Mimpara (cinacalcet), XGEVA (denosumab), Prolia (denosumab), NEUPOGEN (filgrastim), and Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The company specializes in the development of human drugs for the treatment of serious diseases such as tumors and hematological diseases, cardiovascular diseases, inflammation, bone diseases, kidney diseases and neurological diseases. Phase III products developed by the company include Erenumab for paroxysmal migraine, Aranesp for myelodysplastic syndrome, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Company Executives

No Data

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg